Lin Mei, MD
Medical Oncology
Headshot of Lin Mei, MD

Lin Mei, MD

Medical Oncology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 2nd Floor West
View 1 additional location
Headshot of Lin Mei, MD
Penn Medicine Provider

About me

  • Assistant Professor of Clinical Medicine (Hematology-Oncology)

My education and training

  • Peking University Health Science CenterMedical School
  • University at BuffaloResidency
  • Virginia Commonwealth UniversityFellowship

Spoken languages

English
English

Reviews

Average Rating

407 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
October 2026
Felt very comfortable
Anonymous
September 2026
Good Work
Anonymous
September 2026
I'm happy
Anonymous
September 2026
To the point. Appreciated

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Mei is a Penn Medicine provider.

Qualifications and experience

All conditions and treatments

Research

Publications

Khorasanchi A, Mullick Chowdhury S, Fei Hong E, Li M, Jiang C, Mei L, Liu MA, Collier KA, Shang C, Xu L, Manne A, Wang P, Jaroniec S, Gong M, Singer EA, Hong F, Kim H, Niazi K, Wesolowski R, Rubinstein M, Yang Y, Meng L. Circulating Tumor DNA Clearance Is Associated with Response and Survival in Metastatic Urothelial Carcinoma Treated with First-Line Enfortumab Vedotin Plus Pembrolizumab , Cancers, 18(21): 2026,3532


Meng L, Malone X, Peng H, Mei L, Jiang C, Liu X, Wang QE, Hong F, Sood A, Wang SJ, Wu Q, Wang S, Wang P. Racial Disparities in Survival Outcomes for Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A SEER-Based Retrospective Analysis (2010-2020) , Cancers (Basel), 18: 2026,2884


Du W, Koga S, Walle S, Mei L, Baloch Z. Clinicopathologic, immunohistochemical, and molecular correlates in resected primary adrenocortical carcinoma: a single-institution cohort study , Virchows Arch: 2026


Flaig TW, Spiess PE, Abern M, An Y, Bangs R, Begovic J, Brown J, Buyyounouski MK, Chan K, Chang P, Chin AI, Guru KA, Herr HW, Hoffman-Censits J, Kaimakliotis H, Kundu S, Lele SM, Luckenbaugh A, Maldonado J, Mei L, Montgomery JS, Parikh M, Patterson A, Peyton C, Plimack ER, Preston MA, Richards K, Seyedin S, Siefker-Radtke AO, Stewart T, Sundi D, Swami U, Tollefson M, Wright JL, Cassara CJ, Sliker B. Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology , J Natl Compr Canc Netw: 2026


Litt HK, Wodzinski A, Subramanian P, Donovan M, Vapiwala N, Narayan V, Mei L, Takvorian S, Haas NB, Parikh RB, Mistry R, Mamtani R. OncoEducate: A Pilot Study of Generative AI to Enhance Patient-Clinician Communication in Genitourinary Cancer Care , Oncologist: 2026


Nair RP, Du W, Mei L, Koga S. Artificial intelligence for detection, grading, and prognostication in prostate cancer pathology: A scoping review , Histol Histopathol: 2026


Mo G, Maier S, Doyle M, Sweeney S, Orellana J, Farago L, Lloyd A, Mawema H, Bajaj A, Mei L, Takvorian SU, Haas NB, Ky B, Leong D, Narayan V. Cardiovascular risk evaluation in men with prostate cancer study (CARE-PC): Pilot study to assess patient awareness and risk mitigation. , 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium, San Fran, CA.: 2026


Litt HK, Wodzinski A, Subramanian P, Donovan M, Vapiwala N, Parikh RB, Narayan V, Mei L, Takvorian SU, Balzer Haas N, Mistry R, and Mamtani R. OncoEducate: A pilot study of generative AI to support patient education in GU cancer care. , 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium, San Fran, CA., 44(7): 2026,713


Subramanian P, Barsouk A, Elghawy O, Sussman JH, Yaskolko M, Yang A, Xu J, and Mei L. EGFR, HER2 alterations in advanced urothelial carcinoma (aUC): A retrospective analysis on survival outcomes. , American Society of Clinical Oncology Genitourinary Cancers Symposium, San Fran, CA., 44(7): 2026,787


Barsouk AA, Yang A, Sussman JH, Elghawy O, Xu J, Xu J, Meng L, Koga S, Du W, Mamtani R, Mei L. Survival Disparities by Sex, Race, and Age in the Era of Contemporary Advanced Urothelial Carcinoma Therapy: A Real-World Analysis , Clin Genitourin Cancer, 23(5): 2025,102395